WithdrawnPhase 1NCT02639767
Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Marjorie Zauderer, M.DMemorial Sloan Kettering Cancer Center
- Intervention
- Pemetrexed/Cisplatin(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2015
Study locations (6)
- Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
- Memorial Sloan Kettering West Harrison, East White Plains, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
- Memoral Sloan Kettering Cancer Center at Phelps, Sleepy Hollow, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02639767 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited